Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Get Free Report) saw some unusual options trading on Wednesday. Investors purchased 4,063 put options on the company. This represents an increase of 2,362% compared to the average daily volume of 165 put options.
Insider Activity at Xenon Pharmaceuticals
In related news, CFO Sherry Aulin sold 18,709 shares of the business’s stock in a transaction dated Wednesday, December 18th. The stock was sold at an average price of $41.21, for a total value of $770,997.89. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Gary Patou sold 4,891 shares of the stock in a transaction that occurred on Friday, November 22nd. The shares were sold at an average price of $41.08, for a total value of $200,922.28. Following the transaction, the director now directly owns 23,573 shares of the company’s stock, valued at approximately $968,378.84. The trade was a 17.18 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.52% of the stock is currently owned by corporate insiders.
Institutional Investors Weigh In On Xenon Pharmaceuticals
A number of institutional investors have recently modified their holdings of the business. Blue Trust Inc. increased its position in shares of Xenon Pharmaceuticals by 174.7% in the third quarter. Blue Trust Inc. now owns 1,008 shares of the biopharmaceutical company’s stock valued at $39,000 after buying an additional 641 shares in the last quarter. Avior Wealth Management LLC purchased a new stake in Xenon Pharmaceuticals during the 4th quarter worth approximately $101,000. nVerses Capital LLC purchased a new position in shares of Xenon Pharmaceuticals in the third quarter valued at approximately $102,000. Mirae Asset Global Investments Co. Ltd. boosted its stake in Xenon Pharmaceuticals by 21.6% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,740 shares of the biopharmaceutical company’s stock worth $106,000 after purchasing an additional 487 shares during the last quarter. Finally, KBC Group NV grew its holdings in shares of Xenon Pharmaceuticals by 39.8% during the fourth quarter. KBC Group NV now owns 2,742 shares of the biopharmaceutical company’s stock worth $107,000 after buying an additional 780 shares in the last quarter. 95.45% of the stock is currently owned by institutional investors and hedge funds.
Xenon Pharmaceuticals Stock Performance
Xenon Pharmaceuticals (NASDAQ:XENE – Get Free Report) last announced its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.81) earnings per share for the quarter, beating the consensus estimate of ($0.82) by $0.01. During the same period in the previous year, the firm earned ($0.73) EPS. As a group, analysts forecast that Xenon Pharmaceuticals will post -3.13 earnings per share for the current year.
Wall Street Analysts Forecast Growth
XENE has been the subject of a number of research analyst reports. Needham & Company LLC reiterated a “buy” rating and set a $60.00 price objective on shares of Xenon Pharmaceuticals in a report on Wednesday, November 13th. Raymond James reaffirmed an “outperform” rating and set a $50.00 target price on shares of Xenon Pharmaceuticals in a research report on Thursday, October 10th. Finally, HC Wainwright reissued a “buy” rating and set a $53.00 price target on shares of Xenon Pharmaceuticals in a research report on Thursday, December 12th. Seven research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $56.00.
View Our Latest Research Report on Xenon Pharmaceuticals
Xenon Pharmaceuticals Company Profile
Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.
See Also
- Five stocks we like better than Xenon Pharmaceuticals
- Stock Trading Terms – Stock Terms Every Investor Needs to Know
- Oracle Announces Game-Changing News for the AI Industry
- What Does Downgrade Mean in Investing?
- Netflix Adds 19 Million Subscribers, Growth Is Far From Over
- Golden Cross Stocks: Pattern, Examples and Charts
- Tempus AI: A Game-Changer in AI-Powered Healthcare
Receive News & Ratings for Xenon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.